Hormonal implications in the development and treatment of prostate cancer.
In this article, the conflicting data concerning the androgen axis and prostate cancer development are reviewed in addition to how this pathway may be exploited to prevent the development of prostate cancer. The expanding role of hormone ablative therapy alone or in conjunction with standard therapies, the controversies of timing of therapy, and the completeness of ablation and its use on an intermittent basis are reviewed.
Ip
Christopher
C
Department of Urology, Mount Sinai School of Medicine, Box 1272, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Hall
Simon J
SJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000502:physiology*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy; D011471:Prostatic Neoplasms / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D012307:Risk Factors; D015398:Signal Transduction
D000726:Androgen Antagonists; D000728:Androgens